Levosimendan inhibits interleukin-1β-induced cell migration and MMP-9 secretion in rat cardiac fibroblasts

European Journal of Pharmacology

Volumn 718, Issue 1-3, 2013, Pages 332-339

  Okada, Muneyoshi ^a   Suzuki, Atsushi ^a   Yamawaki, Hideyuki ^a   Hara, Yukio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Cardiac fibroblasts; Interleukin 1 ; Levosimendan; Matrix metalloproteinase 9; Migration

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYSTEINYLTHREONYLTHREONYLHISTIDINYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLLEUCYLCYSTEINE; GELATINASE B; INTERLEUKIN 1BETA; LEVOSIMENDAN; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL CELL; ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FIBROBLAST; GENE EXPRESSION; HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY;

CARDIAC FIBROBLASTS; INTERLEUKIN-1Β; LEVOSIMENDAN; MATRIX METALLOPROTEINASE-9; MIGRATION;

AMINO ACID SEQUENCE; ANIMALS; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FLAVONOIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDRAZONES; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; OLIGOPEPTIDES; PHOSPHORYLATION; PYRIDAZINES; RATS; RNA, MESSENGER;

EID: 84887072748     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.08.013     Document Type: Article

References (37)

1. B.C. Berk, K. Fujiwara, and S. Lehoux ECM remodeling in hypertensive heart disease Journal of Clinical Investigation 117 2007 568 575 (Pubitemid 46348511)
2. K.A. Boost, S. Hoegl, A. Dolfen, H. Czerwonka, P. Scheiermann, B. Zwissler, and C. Hofstetter Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury Critical Care Medicine 36 2008 1873 1879
3. 2+ sensitizer levosimendan in human myocardium American Journal of Physiology - Heart and Circulatory Physiology 282 2002 H131 H137
4. R.D. Brown, S.K. Ambler, M.D. Mitchell, and C.S. Long The cardiac fibroblast: therapeutic target in myocardial remodeling and failure Annual Review of Pharmacology and Toxicology 45 2005 657 687 (Pubitemid 40261821)
5. R.D. Brown, G.M. Jones, R.E. Laird, P. Hudson, and C.S. Long Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts Biochemical and Biophysical Research Communications 362 2007 200 205 (Pubitemid 47304407)
6. ATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart British Journal of Pharmacology 154 2008 41 50 (Pubitemid 351620393)
7. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart Circulation Research 77 1995 107 113
8. D. Fan, A. Takawale, J. Lee, and Z. Kassiri Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease Fibrogenesis and Tissue Repair 5 2012 15
9. ATP channel British Journal of Pharmacology 156 2009 250 261
10. M. Kivikko, L. Lehtonen, and W.S. Colucci Sustained hemodynamic effects of intravenous levosimendan Circulation 107 2003 81 86 (Pubitemid 36070937)
11. G. Landoni, A. Mizzi, G. Biondi-Zoccai, E. Bignami, P. Prati, V. Ajello, G. Marino, F. Guarracino, and A. Zangrillo Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies Minerva Anestesiologica 76 2010 276 286
12. C.S. Long The role of interleukin-1 in the failing heart Heart Failure Reviews 6 2001 81 94
13. M. Louhelainen, E. Vahtola, H. Forsten, S. Merasto, V. Kyto, P. Finckenberg, H. Leskinen, P. Kaheinen, I. Tikkanen, J. Levijoki, and E. Mervaala Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats Journal of Hypertension 27 2009 2094 2107
14. M. Louhelainen, E. Vahtola, P. Kaheinen, H. Leskinen, S. Merasto, V. Kyto, P. Finckenberg, W.S. Colucci, J. Levijoki, P. Pollesello, H. Haikala, and E.M. Mervaala Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats British Journal of Pharmacology 150 2007 851 861 (Pubitemid 46536624)
15. M.K. MacGillivray, T.F. Cruz, and C.A. McCulloch The recruitment of the interleukin-1 (IL-1) receptor-associated kinase (IRAK) into focal adhesion complexes is required for IL-1β-induced ERK activation Journal of Chemical Biology 275 2000 23509 23515 (Pubitemid 30624632)
16. M.D. Mitchell, R.E. Laird, R.D. Brown, and C.S. Long IL-1β stimulates rat cardiac fibroblast migration via MAP kinase pathways American Journal of Physiology - Heart and Circulatory Physiology 292 2007 H1139 H1147
17. A.C. Newby Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates Cardiovascular Research 69 2006 614 624 (Pubitemid 43140745)
18. M. Nian, P. Lee, N. Khaper, and P. Liu Inflammatory cytokines and postmyocardial infarction remodeling Circulation Research 94 2004 1543 1553 (Pubitemid 38856961)
19. M. Okada, R. Kikuzuki, T. Harada, Y. Hori, H. Yamawaki, and Y. Hara Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats Journal of Pharmacological Sciences 108 2008 487 494
20. M. Okada, H. Yamawaki, and Y. Hara Angiotensin II enhances interleukin-1 β-induced MMP-9 secretion in adult rat cardiac fibroblasts Journal of Veterinary Medical Science 72 2010 735 739
21. E.R. Olson, P.E. Shamhart, J.E. Naugle, and J.G. Meszaros Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase Cδ and intracellular calcium in adult rat cardiac fibroblasts Hypertension 51 2008 704 711 (Pubitemid 351301524)
22. S.S. Ozdem, O. Yalcin, H.J. Meiselman, O.K. Baskurt, and C. Usta The role of potassium channels in relaxant effect of levosimendan in rat small mesenteric arteries Cardiovascular Drugs and Therapy 20 2006 123 127 (Pubitemid 43876095)
23. J.T. Parissis, P. Rafouli-Stergiou, I. Paraskevaidis, and A. Mebazaa Levosimendan: from basic science to clinical practice Heart Failure Reviews 14 2009 265 275
24. S. Phalitakul, M. Okada, Y. Hara, and H. Yamawaki A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells Biochemical and Biophysical Research Communications 423 2012 844 849
25. K.E. Porter, and N.A. Turner Cardiac fibroblasts: at the heart of myocardial remodeling Pharmacology and Therapeutics 123 2009 255 278
26. 2-induced oxidative stress in human myocardium Journal of Cardiovascular Pharmacology 50 2007 419 423 (Pubitemid 350303820)
27. O. Sareila, R. Korhonen, H. Auvinen, M. Hamalainen, H. Kankaanranta, E. Nissinen, and E. Moilanen Effects of levo- and dextrosimendan on NF-κB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli British Journal of Pharmacology 155 2008 884 895
28. K. Schram, R. Ganguly, E.K. No, X. Fang, F.S. Thong, and G. Sweeney Regulation of MT1-MMP and MMP-2 by leptin in cardiac fibroblasts involves Rho/ROCK-dependent actin cytoskeletal reorganization and leads to enhanced cell migration Endocrinology 152 2011 2037 2047
29. D.A. Siwik, D.L. Chang, and W.S. Colucci Interleukin-1β and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro Circulation Research 86 2000 1259 1265 (Pubitemid 30436667)
30. ATP channel and potential pERK 1/2 activation European Journal of Pharmacology 655 2011 59 66
31. F.G. Spinale Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiological Reviews 87 2007 1285 1342 (Pubitemid 350041472)
32. K. Todaka, J. Wang, G.H. Yi, R. Stennett, M. Knecht, M. Packer, and D. Burkhoff Effects of levosimendan on myocardial contractility and oxygen consumption Journal of Pharmacology and Experimental Therapeutics 279 1996 120 127 (Pubitemid 27166902)
33. T. Tsuruda, L.C. Costello-Boerrigter, and J.C. Burnett Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules Heart Failure Reviews 9 2004 53 61 (Pubitemid 38196077)
34. D.N. Tziakas, G.K. Chalikias, H.I. Hatzinikolaou, D.A. Stakos, N. Papanas, I.K. Tentes, A.X. Kortsaris, E. Maltezos, D.I. Hatseras, and J.C. Kaski Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure Cardiovascular Drugs and Therapy 19 2005 399 402 (Pubitemid 43228151)
35. Y. Wang, F. Xu, J. Chen, X. Shen, Y. Deng, L. Xu, J. Yin, H. Chen, F. Teng, X. Liu, W. Wu, B. Jiang, and D.A. Guo Matrix metalloproteinase-9 induces cardiac fibroblast migration, collagen and cytokine secretion: inhibition by salvianolic acid B from Salvia miltiorrhiza Phytomedicine 19 2011 13 19
36. Z. Xie, M. Singh, and K. Singh Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β Journal of Chemical Biology 279 2004 39513 39519 (Pubitemid 39258218)
37. + channel in rat ventricular cells Journal of Pharmacology and Experimental Therapeutics 283 1997 375 383 (Pubitemid 27438984)